1.77
-0.075(-4.08%)
Currency In USD
| Previous Close | 1.84 |
| Open | 1.81 |
| Day High | 1.84 |
| Day Low | 1.76 |
| 52-Week High | 2.7 |
| 52-Week Low | 1.18 |
| Volume | 773,808 |
| Average Volume | 1.63M |
| Market Cap | 469.74M |
| PE | -1.62 |
| EPS | -1.09 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.54 |
| Change | -0.08 |
Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus anticipates full year 2026 AUCATZYL® net product revenue of
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Dec 08, 2025 9:05 PM GMT
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting an immune